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Introduction and background
===========================

The polycystic ovarian syndrome affects women of childbearing age and is a clinical diagnosis. The etiology of the polycystic ovarian syndrome is unknown but may be attributed to insulin resistance. Patients frequently present with symptoms such as menstrual irregularities, androgen excess, and polycystic ovaries. While androgen excess often presents with acne and hirsutism, menstrual irregularities often lead to infertility. Treating menstrual irregularities is a crucial component to the polycystic ovarian syndrome. Menstrual irregularities caused by polycystic ovaries leads to infertility, resulting in distress among women trying to conceive \[[@REF1]-[@REF3]\]. 

Hormonal pharmacologic therapies such as oral contraceptives have been used for the treatment of menstrual irregularities in polycystic ovarian syndrome. In addition to hormone therapy, metformin was used to treat irregular menses in females with a history of oligo-menorrhea or amenorrhea. The exact mechanism of metformin in regulating menstrual cycle is still unknown. However, it may be attributed to insulin sensitization thereby targeting the insulin resistance caused by androgen excess \[[@REF1]-[@REF3]\]. This literature review is aimed to determine the effectiveness of metformin in regulating menstrual cycles among females with the polycystic ovarian syndrome.

Review
======

Method 

The data was collected from PubMed using regular keywords "polycystic ovary" and "metformin." The following inclusion criteria were applied in the following order - literature published within 10 years, articles involving only human subjects, articles published only in English language and the age of the subjects 19 years or more. The collection of the articles for the study was done ethically.

Results

After using regular keywords on PubMed, a total of 1550 articles were identified. Among the 1550 articles, 347 were obtained with the application of filters. Table [1](#TAB1){ref-type="table"} shows the total number of articles obtained in order after applying inclusion criteria in PubMed.

###### Keywords search after applying inclusion criteria in PubMed

  -------------------------- ---------
  Articles                   Results
  Total articles found       1550
  After inclusion criteria    
  10 years                   890
  Humans                     706
  English language           658
  Age 19 or more             347
  -------------------------- ---------

Of the 347 articles obtained, each article was individually reviewed based on the abstract content. Three hundred and twenty-two articles were not selected for review due to one or more of the following reasons:

\- lack of disease of interest;

\- lack of menstrual irregularities;

\- lack of metformin use for menstrual irregularity;

\- studies with no possible derivation of information with quality assessment.

The number of articles obtained after removal of 322 articles was 25, among which 16 were free abstracts available online for review and nine were free with full text available online for review. Of the articles included in the data, there were 21 randomized controlled trials, two literature reviews, and one systemic review.

In addition to metformin, other drugs used as comparators in the randomized clinical trials were clomiphene citrate, oral contraceptives, ethinylestradiol, desogestrel, simvastatin, rosiglitazone, orlistat, n-acetylcysteine, letrozole, calcium & vitamin D, pioglitazone, saxagliptin, spironolactone, flutamide, lipoic acid, monacolin K and myo-inositol. Non-pharmacologic therapies used in clinical trials were lifestyle modifications such as caloric restriction and exercise \[[@REF3]-[@REF12]\]. 

The 25 selected articles showed evidence for metformin therapy to be efficacious in regulating menstrual cycles of females with the polycystic ovarian syndrome. When metformin was used with other pharmacologic agents, there was a recovery of menstrual cycles as well. Of the articles collected, the randomized clinical trials involving metformin showed improvement in menstrual cycle irregularity with metformin \[[@REF3], [@REF10]-[@REF17]\]. Table [2](#TAB2){ref-type="table"} shows the analysis of various parameters seen in the randomized clinical trials.

###### Analysis of various parameters

mg - milligram; LH - luteinizing hormone; FSH - follicle-stimulating hormone; BID - two times a day; BMI - body mass index; COC - combined oral contraceptives; N/A - not available; TG - triglyceride; HDL - high-density lipoprotein

  ---------------------------------------- ------------ --------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- -------------------------- ---------------------------------------------------------------------- ------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  Randomized Controlled Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Author/Year                              Population   Metformin (dose in mg if applicable)    Arms                                                                                                                         Length of Study (Months)   Results                                                                                                                                                                                                                                            
  Menses                                   LH/FSH       Weight                                  Testosterone                                                                                                                 Other                                                                                                                                                                                                                                                                         
  Seyam et al. 2018 \[[@REF16]\]           65           500 mg three times daily                Group A simvastatin + metformin, group B simvastatin, group C metformin                                                      12                         Improved                                                               Decrease serum LH level                     Decrease BMI                                                              Decrease                                              Decrease of total cholesterol, low-density lipoprotein, triglycerides, increase in high-density lipoprotein decreased hirsutism, acne, ovarian volume
  Alpañés et al. 2017 \[[@REF3]\]          22           850 mg BID                              Group with combined oral contraceptive (COC) plus spironolactone versus metformin                                            12                         Menstrual dysfunction was less frequent with COC plus spironolactone   N/A                                         N/A                                                                       Total testosterone,  free testosterone                COC + spironolactone showed more decrease in hirsutism, androstenedione, dehydroepiandrosterone sulphate
  Tagliaferri et al. 2017 \[[@REF11]\]     34           850 mg BID                              Group metformin versus myoinositol                                                                                           6                          Improved menstrual pattern with metformin                              Metformin showed LH significant decreased   Metformin showed a decrease in weight                                     N/A                                                   Metformin showed a decrease in estradiol levels and androgens
  Elkind-Hirsch et al. 2017 \[[@REF17]\]   3            2,000 mg                                Combined saxagliptin 2,000 mg-metformin 5 mg, saxagliptin 5 mg, or metformin 2,000 mg                                        4                          Saxagliptin-metformin greatly improved the menstrual irregularity      N/A                                         BMI, waist/height ratio and waist circumference decreased in all groups   N/A                                                   Significant decrease in triglyceride, TG/HDL cholesterol ratio, and blood glucose level in the saxagliptin-metformin and saxagliptin groups only
  Mazza et al. 2014 \[[@REF12]\]           28           1700 mg                                 Group A metformin (1700 mg/day), group B with metformin (1700 mg/day) + spironolactone (25 mg/day)                           N/A                        Menses improved more in metformin 1700 mg a day                        N/A                                         N/A                                                                       Significant decrease in testosterone in both groups   Significant decrease in group A and B of androstenedione and hirsutism
  Firouzabadi et al. 2012 \[[@REF13]\]     50           1500 mg/day                             Group I metformin 1500 mg a day, group II metformin 1500 mg a day + calcium 1000 mg a day + vitamin D 100000 IU per month    6                          Menses improved more in metformin 1500 mg a day                        N/A                                         Significant decrease in BMI in group II                                   N/A                                                   Follicle maturation, and infertility improved group II \> group I
  ---------------------------------------- ------------ --------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- -------------------------- ---------------------------------------------------------------------- ------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------

Irrespective of the dosage, it is observed that even at a 500 mg dosage, metformin therapy showed improvement in regulating menstrual cycles. In addition, metformin also showed a decrease of hormone levels such as luteinizing hormone (LH), luteinizing hormone/follicle-stimulating hormone (LH/FSH) ratio, testosterone, estradiol, dehydroepiandrosterone sulfate (DHEA-S) and progesterone. Furthermore, metformin was effective in weight reduction and hirsutism \[[@REF15], [@REF18]-[@REF19]\].

Table [3](#TAB3){ref-type="table"} below illustrates the effects seen with metformin monotherapy at various doses in the following randomized clinical trials in patients with polycystic ovarian syndrome.

###### Randomized clinical trials involving monotherapy of metformin at various doses

mg - milligram; LH - luteinizing hormone; FSH - follicle-stimulating hormone; BID - two times a day; TID - three times a day; BMI - body mass index; CRP - c-reactive protein; DHEA-S - dehydroepiandrosterone sulfate; N/A - not available

  ------------------------------------------------ ---------------- ------------------------------------------------------------------------------------------------ ---------------------------- ------------------------------------------------- ---------------------- ------------------------------------------ ---------------------------------------------------------------------------- -------------------------------------------------------------
  Randomized Control Trial with metformin only                                                                                                                                                                                                                                                                                                                                                     
  Author/ Year                                       Population     Dose (mg)                                                                                        Length of Study (Months)     Results                                                                                                                                                                                          
  Menses                                           LH/FSH           Weight                                                                                           Testosterone                 Other                                                                                                                                                                                            
  Fulghesu et al. 2012 \[[@REF15]\]                201              500 mg BID, 500 mg TID, 850 mg BID                                                               6                            Increase of more than two menstrual cycles/year   N/A                    N/A                                        Greater reduction in plasma testosterone levels who had a higher basal BMI   N/A
  Yang et al. 2018 \[[@REF18]\]                    119              The first month 500 mg once; the second month 1000 mg once; third month & onwards 1500 mg once   24                           Increased frequency                               Decreased LH           Decreased BMI                              Decreased                                                                    N/A
  Velija-Ašimi et al. 2013 \[[@REF19]\]            100              1000-1500 mg BID/TID                                                                             12                           Restored                                          Decreased LH, LH/FSH   Reduced weight, waist circumference, BMI   Decreased                                                                    Decrease estradiol, CRP, DHEA-S and progesterone, hirsutism
  ------------------------------------------------ ---------------- ------------------------------------------------------------------------------------------------ ---------------------------- ------------------------------------------------- ---------------------- ------------------------------------------ ---------------------------------------------------------------------------- -------------------------------------------------------------

Conclusions
===========

The objective of the current literature review is to determine the effectiveness of metformin in regulating menstrual cycles among women diagnosed with the polycystic ovarian syndrome experiencing irregular menses. The use of metformin has demonstrated an improvement in regulating menses significantly with a greater improvement when metformin is used as an adjunctive to another pharmacologic agent. It is to be determined whether these patients will require lifelong metformin therapy or if insulin sensitization can be achieved at a specific number of doses required thereby leaving room for speculation if metformin can be halted after a certain number of doses. One wonders if metformin's effect at regulating menses is tied with insulin sensitization and if serum testosterone plays a role. 
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